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cardiac surgery training programs. Hence, a majority of graduating
and practicing cardiac surgeons lack the necessary skills to rou-
tinely incorporate endovascular procedures into their practice.
Cardiac surgeons, cardiologists, interventional radiologists, and
vascular surgeons should unite to develop multispecialty endovas-
cular training programs and determine national credentialing
standards for carotid stenting. Moreover, cardiac surgeons must
take advantage of this opportunity to address the broader issue of
endovascular training within our specialty. Vascular surgery has
already incorporated endovascular experiences into their training
regimens. As a result, many graduating vascular surgery residents
possess catheter-based skills and are engaged in the practice of
“endovascular surgery.” The American Board of Thoracic Surgery
should consider adding an endovascular component to the gradu-
ating certification requirements. Cardiac surgeons can currently
obtain training in catheter-based procedures only through a
limited number of nonaccredited fellowships. If cardiac surgeons
are to be realistically involved in catheter-based procedures (and they
should), it is time that cardiac surgery training programs either: 1) add
individuals to their faculty with advanced endovascular skills; 2)
encourage existing faculty to retrain in catheter-based procedures; or
3) allow their residents to spend quality time during their residency
with clinicians who have extensive endovascular experience.
Who performs carotid stenting is a highly charged issue, and
perhaps it will be the sentinel event that can bring diverse
specialties together to create a national standard for training and
credentialing in endovascular procedures. I believe the optimal
solution will be a multidisciplinary based approach, so that
qualified physicians from a number of specialties will be able to
offer carotid stenting to their patients. Working through these
issues now will also potentially make the introduction and dissem-
ination of newer catheter-based therapies, such as percutaneous
valves and cellular therapies for heart failure, more straightforward
and less contentious.
*Grayson H. Wheatley III, MD
*Department of Cardiovascular and Thoracic Surgery
University of Texas Southwestern
5939 Harry Hines Boulevard
HA-9, Suite 135
Dallas, TX 75390-8879
E-mail: gwheat@parknet.pmh.org
doi:10.1016/j.jacc.2004.10.024
REFERENCE
1. Gray WA. A cardiologist in the carotids. J Am Coll Cardiol
2004;43:1602–5.
REPLY
Dr. Wheatley’s letter appropriately raises several important issues
related to carotid stenting, and the potential operators and path-
ways to becoming expert in this emerging field. However, my
editorial (1) did not suggest cardiologists should be alone at the
forefront of the “new wave” of carotid stenting. New operators are
not assigned; rather, they declare themselves by virtue of interest,
dedication, practice type, access to patients, training, and, yes, skill
sets. It is noteworthy, however, that the significant majority of
carotid stenting performed worldwide and in this country has been
by cardiologists and that both device development and the pivotal
research owe much to that specialty (2). We would not be having
this and other debates about specialty involvement had cardiology
folded its tents under the barrage of criticism it received and had
not proven the efficacy of carotid stenting.
Inclusion of cardiac surgeons to the current potpourri of
cardiologists, vascular surgeons, radiologists, neurointerventional-
ists, neurosurgeons, and neurologists currently claiming a role in
carotid stenting is not a priori a nonstarter. However, cardiac
surgeons will be held to the same standards by most local hospital
credentialing committees. This generally means that they will need
to have all the requisite catheter-based skills (access, angioplasty,
stenting, wire manipulation, etc.) that are generally acquired by
noncardiologists by the performance of peripheral intervention.
Further, they will need the rapid exchange and 0.014-inch wire
experience necessary to move to carotid equipment. Practically
speaking, access to the carotid patients and the ability to assess
their clinical indications for carotid revascularization via interpre-
tation of the various imaging modes currently available, the
performance and interpretation of cerebral angiography, and judg-
ing the clinical appropriateness of any, and which, carotid inter-
vention (surgical or endovascular) involves new cognitive skills that
are achievable but require a dedicated effort. Finally, working on
nonanesthetized patients has been a test for several specialties
entering this field who are generally accustomed to it.
Although it appears that cardiac surgery may, in fact, be one of
the specialties most challenged when it comes to making up the
current deficits outlined above, Dr. Wheatley raises an important
point: acquiring these requisite skills will serve the surgeon well as
other technologies currently in development (percutaneous valve
therapies, heart failure devices, and so forth) emerge for patients they
are currently operating on. These skills will better position them to
take part in, rather than to lose, the care of these patients. I would
suggest those skills could be achieved without performing carotid
stenting, where the consequences of complications may be irretriev-
able even by the surgeon and are devastating for all involved.
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Advantage of Percutaneous Coronary
Intervention Over Medical Therapy
in Angina Relief and the Placebo Effect
In the Medicine, Angioplasty, or Surgery Study (MASS-II)
recently published in the Journal, Hueb et al. (1) compared the
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relative efficacies of three possible therapeutic strategies (e.g.,
Coronary artery bypass graft surgery [CABG], percutaneous cor-
onary intervention [PCI], and medical therapy [MT]) for patients
with multivessel coronary artery disease (CAD), stable angina, and
preserved ventricular function.
At one-year follow-up, 79% in the PCI group and 46% in the
MT group were free of angina. Medical therapy, however, was
associated with a lower incidence of short-term events (e.g.,
myocardial infarction or death) and a reduced need for additional
revascularization, compared with PCI (1).
It appears that patients allocated to the different arms were not
blinded to the treatment prescribed, which means that both PCI
and medically treated patients were aware of the fact that they did
or did not undergo mechanical intervention. Thus, the superiority
of PCI compared to MT as an antiangina therapy may at least
partially be due to the placebo effect. Similar placebo effect may
also affect the results of the Second Randomized Intervention
Treatment of Angina (RITA-2) study (2) for the same reason.
The placebo effect can be powerful indeed, as was proven in the
case of percutaneous transmyocardial revascularization (PTMR):
after a few unblinded, randomized trials of PTMR, patients with
refractory angina demonstrated significant relief of angina. A
well-conducted blinded randomized study, however, showed
PTMR does not result in a greater reduction in angina, as
compared with MT (3).
If the placebo effect is responsible, even in part, for angina relief
by PCI, then PCI is an even less appealing option for patients with
multivessel CAD, stable angina, and preserved ventricular func-
tion, considering the lower incidence of short-term events associ-
ated with MT, demonstrated by the MASS-II study.
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We thank Dr. Rott for his comments regarding our article (1). In
the MASS-II study, 59% of patients treated with coronary artery
bypass graft surgery (CABG) and 52% treated percutaneously were
free of angina at one year, figures significantly better than the 36%
of patients without symptoms in the medically treated group (with
no difference between surgery and stenting). As pointed out by Dr.
Rott, a placebo effect related to the invasive nature of the former
modalities cannot be ruled out as a possible component to justify
the symptomatic improvement among these patients. However, we
should emphasize that the difference in the symptomatic status of
the study groups was paralleled by a highly significant reduction in
the rate of objective ischemia among the groups, which was greater
for the surgical and percutaneous groups (36% and 18%, respec-
tively) than for medically treated patients (5%). Therefore, we trust
that most (if not all) of the symptom relief observed among
patients treated with myocardial revascularization might have been
related to actual ischemia reduction.
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